GlassScriptPhysician profile
James C Loos
NPI 1801991476
$2,998.11
in general payments reported to CMS, 2019-2025
24 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $96.33 · 2021: $59.38 · 2022: $255 · 2023: $218 · 2024: $1,417 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086 · Travel and Lodging: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.05 |
| Travel and Lodging | $906.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,124.75 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $230.19 | 2019-2025 | Ams 700, Lithovue Elite |
| Abbvie INC. | $208.56 | 2019-2025 | |
| Janssen Biotech, INC. | $186.36 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Pfizer INC. | $157.30 | 2019-2025 | |
| Allergan, INC. | $146.36 | 2019-2020 | |
| Coloplast Corp | $143.84 | 2021-2025 | Self-Cath |
| 180 Medical, INC. | $117.09 | 2022-2025 | Cure Catheter |
| Endo Pharmaceuticals INC. | $115.28 | 2019-2022 | |
| Astellas Pharma US INC | $97.28 | 2019 | |
| Olympus America INC. | $70.00 | 2022 | |
| Urogen Pharma, INC. | $57.20 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $50.62 | 2019 | |
| Sumitomo Pharma America, INC. | $39.18 | 2023 | Orgovyx, Gemtesa |
| Teleflex LLC | $33.66 | 2023-2024 | Urolift |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Profound Medical Corp. | $31.88 | 2022 | |
| Antares Pharma, INC. | $31.15 | 2019 | |
| Tolmar, INC. | $29.99 | 2025 | Jatenzo, Eligard |
| Ethicon US, LLC | $25.85 | 2024 | Stratafix |
| Myovant Sciences INC. | $24.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.50 | 2022 | |
| Travere Therapeutics, INC. | $15.64 | 2019-2022 | |
| Axonics, INC. | $14.35 | 2023 | Bulkamid, Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Loos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.